Nigel Vicker

2.0k total citations
48 papers, 1.7k citations indexed

About

Nigel Vicker is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Organic Chemistry. According to data from OpenAlex, Nigel Vicker has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 20 papers in Endocrinology, Diabetes and Metabolism and 16 papers in Organic Chemistry. Recurrent topics in Nigel Vicker's work include Hormonal Regulation and Hypertension (20 papers), Estrogen and related hormone effects (15 papers) and Pharmacogenetics and Drug Metabolism (8 papers). Nigel Vicker is often cited by papers focused on Hormonal Regulation and Hypertension (20 papers), Estrogen and related hormone effects (15 papers) and Pharmacogenetics and Drug Metabolism (8 papers). Nigel Vicker collaborates with scholars based in United Kingdom, France and New Zealand. Nigel Vicker's co-authors include Barry V. L. Potter, Michael Reed, Atul Purohit, Helena J. Tutill, Harshani R. Lawrence, Andrew Smith, G.M. Allan, Xiangdong Su, Joanna M. Day and Chung S. Kim and has published in prestigious journals such as Journal of the American Chemical Society, Biochemistry and Biochemical Journal.

In The Last Decade

Nigel Vicker

48 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nigel Vicker United Kingdom 25 878 666 405 392 280 48 1.7k
René Maltais Canada 20 316 0.4× 599 0.9× 561 1.4× 349 0.9× 117 0.4× 84 1.1k
Martin Frotscher Germany 19 359 0.4× 390 0.6× 722 1.8× 686 1.8× 166 0.6× 46 1.2k
Antonio Mouriño Spain 28 1.2k 1.4× 509 0.8× 419 1.0× 160 0.4× 67 0.2× 143 2.4k
R. MCCAGUE United Kingdom 20 566 0.6× 564 0.8× 537 1.3× 84 0.2× 178 0.6× 54 1.4k
Erwin von Angerer Germany 29 1.4k 1.6× 713 1.1× 591 1.5× 116 0.3× 64 0.2× 94 2.4k
Jenny Roy Canada 17 250 0.3× 333 0.5× 338 0.8× 181 0.5× 108 0.4× 61 790
J. T. Link United States 21 1.3k 1.5× 593 0.9× 58 0.1× 184 0.5× 186 0.7× 42 2.0k
János Wölfling Hungary 26 1.5k 1.7× 1.1k 1.6× 567 1.4× 100 0.3× 127 0.5× 156 2.2k
Gyula Schneider Hungary 26 1.3k 1.5× 956 1.4× 551 1.4× 91 0.2× 125 0.4× 145 1.9k
Gary H. Rasmusson United States 24 376 0.4× 808 1.2× 256 0.6× 896 2.3× 188 0.7× 45 1.9k

Countries citing papers authored by Nigel Vicker

Since Specialization
Citations

This map shows the geographic impact of Nigel Vicker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Vicker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Vicker more than expected).

Fields of papers citing papers by Nigel Vicker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Vicker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Vicker. The network helps show where Nigel Vicker may publish in the future.

Co-authorship network of co-authors of Nigel Vicker

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Vicker. A scholar is included among the top collaborators of Nigel Vicker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Vicker. Nigel Vicker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Su, Xiangdong, Heather Halem, Mark Thomas, et al.. (2012). Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Bioorganic & Medicinal Chemistry. 20(21). 6394–6402. 10 indexed citations
2.
Su, Xiangdong, Nigel Vicker, Mark Thomas, et al.. (2011). Discovery of Adamantyl Heterocyclic Ketones as Potent 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitors. ChemMedChem. 6(8). 1439–1451. 8 indexed citations
3.
Su, Xiangdong, Fabienne Pradaux, Nigel Vicker, et al.. (2011). Adamantyl Ethanone Pyridyl Derivatives: Potent and Selective Inhibitors of Human 11β‐Hydroxysteroid Dehydrogenase Type 1. ChemMedChem. 6(9). 1616–1629. 12 indexed citations
4.
Su, Xiangdong, Fabienne Pradaux, Mark Thomas, et al.. (2010). Discovery of Adamantyl Ethanone Derivatives as Potent 11β‐Hydroxysteroid Dehydrogenase Type 1 (11β‐HSD1) Inhibitors. ChemMedChem. 5(7). 1026–1044. 14 indexed citations
5.
Day, Joanna M., Paul Foster, Helena J. Tutill, et al.. (2008). 17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer. International Journal of Cancer. 122(9). 1931–1940. 100 indexed citations
6.
Day, Joanna M., Helena J. Tutill, Paul Foster, et al.. (2008). Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3. Molecular and Cellular Endocrinology. 301(1-2). 251–258. 14 indexed citations
7.
Allan, G.M., Nigel Vicker, Harshani R. Lawrence, et al.. (2008). Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design. Bioorganic & Medicinal Chemistry. 16(8). 4438–4456. 38 indexed citations
8.
Vicker, Nigel, Ana Ramos, Joanna M. Day, et al.. (2008). The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors. Molecular and Cellular Endocrinology. 301(1-2). 259–265. 25 indexed citations
9.
Su, Xiangdong, Nigel Vicker, & Barry V. L. Potter. (2008). 2 Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1. Progress in medicinal chemistry. 46. 29–130. 15 indexed citations
10.
Vicker, Nigel, Xiangdong Su, Dharshini Ganeshapillai, et al.. (2007). Novel non-steroidal inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. The Journal of Steroid Biochemistry and Molecular Biology. 104(3-5). 123–129. 25 indexed citations
11.
Purohit, A., Helena J. Tutill, Joanna M. Day, et al.. (2006). The regulation and inhibition of 17β-hydroxysteroid dehydrogenase in breast cancer. Molecular and Cellular Endocrinology. 248(1-2). 199–203. 22 indexed citations
12.
Vicker, Nigel, Harshani R. Lawrence, G.M. Allan, et al.. (2006). Focused Libraries of 16‐Substituted Estrone Derivatives and Modified E‐Ring Steroids: Inhibitors of 17ß‐Hydroxysteroid Dehydrogenase Type 1. ChemMedChem. 1(4). 464–481. 37 indexed citations
13.
Fischer, Delphine S., G.M. Allan, Christian Bubert, et al.. (2005). E-Ring Modified Steroids as Novel Potent Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1. Journal of Medicinal Chemistry. 48(18). 5749–5770. 76 indexed citations
14.
Su, Xiangdong, Nigel Vicker, Dharshini Ganeshapillai, et al.. (2005). Benzothiazole derivatives as novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology. 248(1-2). 214–217. 55 indexed citations
15.
Su, Xiangdong, Harshani R. Lawrence, Dharshini Ganeshapillai, et al.. (2004). Novel 18β-glycyrrhetinic acid analogues as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenases. Bioorganic & Medicinal Chemistry. 12(16). 4439–4457. 47 indexed citations
16.
Vicker, Nigel, Xiangdong Su, Harshani R. Lawrence, et al.. (2004). A novel 18β-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 2. Bioorganic & Medicinal Chemistry Letters. 14(12). 3263–3267. 19 indexed citations
17.
Vicker, Nigel, et al.. (2003). Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorganic & Medicinal Chemistry Letters. 13(5). 863–865. 31 indexed citations
18.
Purohit, A., Nigel Vicker, Stephen T. Newman, et al.. (2003). Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochemical and Biophysical Research Communications. 305(4). 909–914. 61 indexed citations
19.
Grigg, Ronald, et al.. (2001). One-pot sequential and cascade formation of triazoles via palladium catalysed azide capture-1,3-dipolar cycloaddition. Tetrahedron. 57(36). 7729–7735. 39 indexed citations
20.
Stoll, Mark S., Nigel Vicker, C. H. Gray, & Raymond Bonnett. (1982). Concerning the structure of photobilirubin II. Biochemical Journal. 201(1). 179–188. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by René Maltais Breakdown of academic impact, for papers by Martin Frotscher Breakdown of academic impact, for papers by Antonio Mouriño Breakdown of academic impact, for papers by R. MCCAGUE Breakdown of academic impact, for papers by Erwin von Angerer Breakdown of academic impact, for papers by Jenny Roy Breakdown of academic impact, for papers by J. T. Link Breakdown of academic impact, for papers by János Wölfling Breakdown of academic impact, for papers by Gyula Schneider Breakdown of academic impact, for papers by Gary H. Rasmusson
Rankless by CCL
2026